An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 1 February, 2015 by The TZ Newswire Staff

An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?

The healthcare gurus known as the Baker Brothers have amassed a huge position in the orphan drugmaker Synageva BioPharma Corp. Should investors follow in their footsteps?

See also
- Next Article Duke Energy Stock Has Doubled Since It Broke Up With Coal, But is the Rebound at Risk?
- Previous Article 1 Chart Every Bank Investor Needs to See
Editorial Calender

February 2015

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28

« Jan Mar »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 1 February, 2015 by The TZ Newswire Staff

An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?

See also

Editorial Calender

Recent Tags